ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 9 Issue 4, Winter 1995

January 12, 1995

FDA Forms Office of Combination Products;

January 10, 2003

Funding Opportunities: ONS Biotherapy Phase II, Outcomes-Research Grant

August 3, 2001

Congressional News: Senate Subcommittee Recommends $2.3 Bil. Budget for NCI

September 13, 1996

DCPC Board Ponders Screening Recommendations: Should NCI Have Policies? If So, What Will They Be?

September 26, 1986

Community Cancer Center Group Formed to Deal With “Toad-Like Pace Of NCI,” Other Problems

June 7, 1974